The quest for efficacy in pancreatic cancer
Late-stage therapies from Fibrogen, Tyme and Novartis need to avoid the same pitfalls as Erytech and Rafael.
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Clinical data focus for the smallest players
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Success still eludes pancreatic cancer pipeline
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.